# A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia

> **NCT01150448** · PHASE1 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 212 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Paliperidone palmitate Treatment A
- **DRUG:** Paliperidone palmitate Treatment B

## Key facts

- **NCT ID:** NCT01150448
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 212 (ACTUAL)
- **Last updated:** 2014-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01150448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01150448, "A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01150448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*